State Street Corp Boosts Holdings in Immunic, Inc. (NASDAQ:IMUX)

State Street Corp grew its position in Immunic, Inc. (NASDAQ:IMUX) by 7.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 167,145 shares of the company’s stock after acquiring an additional 11,642 shares during the quarter. State Street Corp owned about 0.19% of Immunic worth $276,000 at the end of the most recent reporting period.

Separately, Connor Clark & Lunn Investment Management Ltd. raised its position in Immunic by 70.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock worth $169,000 after purchasing an additional 42,383 shares during the period. Institutional investors and hedge funds own 51.82% of the company’s stock.

Analyst Ratings Changes

Several research analysts have issued reports on the company. EF Hutton Acquisition Co. I upgraded Immunic to a “strong-buy” rating in a research report on Monday, September 16th. Leerink Partners reaffirmed an “outperform” rating and issued a $5.00 price objective on shares of Immunic in a research report on Monday, September 9th. Leerink Partnrs upgraded Immunic to a “strong-buy” rating in a research report on Monday, September 9th. StockNews.com cut shares of Immunic from a “hold” rating to a “sell” rating in a report on Monday, November 11th. Finally, HC Wainwright started coverage on shares of Immunic in a research note on Monday, November 25th. They issued a “buy” rating and a $10.00 price target on the stock. One research analyst has rated the stock with a sell rating, five have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $11.80.

Immunic Price Performance

IMUX stock opened at $1.10 on Friday. Immunic, Inc. has a 1-year low of $0.97 and a 1-year high of $2.11. The business has a 50-day moving average price of $1.15 and a 200 day moving average price of $1.32. The company has a market capitalization of $99.09 million, a P/E ratio of -0.89 and a beta of 1.89.

Insider Buying and Selling at Immunic

In related news, Director Richard Alan Rudick bought 87,300 shares of the company’s stock in a transaction on Tuesday, November 12th. The shares were acquired at an average price of $1.15 per share, with a total value of $100,395.00. Following the transaction, the director now owns 87,300 shares of the company’s stock, valued at $100,395. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 3.00% of the company’s stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.